Current status of acid pump antagonists (reversible PPIs)

Area of Science:

• Pharmacology and Gastroenterology
• Drug Discovery and Development

Background:

• H2-receptor antagonists provided initial medical therapy for acid-related diseases but had limitations.
• Proton pump inhibitors (PPIs) offer effective gastric acid control by inhibiting H+, K(+)-ATPase.
• Limitations of PPIs necessitate exploration of alternative mechanisms for acid suppression.

Purpose of the Study:

• To evaluate the efficacy and pharmacodynamics of a novel acid pump antagonist (APA), BY841.
• To compare the antisecretory effects of BY841 with existing treatments like ranitidine and omeprazole.
• To assess the dose-dependency and duration of action of BY841 in preclinical and clinical models.

Main Methods:

• Pharmacological experiments including pH-metry in pentagastrin-stimulated fistula dogs.
• Chemical characterization of BY841 as an imidazopyridine APA.
• Clinical Phase I studies involving acid output and 24-hour pH measurements in humans.

Main Results:

• BY841 rapidly elevated intragastric pH to 6 in dogs, outperforming ranitidine and omeprazole.
• Clinical data confirmed dose-dependent pharmacodynamics of BY841, with a single 50 mg dose raising pH to 6.
• BY841 showed sustained efficacy, improved by twice-daily dosing and repeated administration, without tolerance development, and was more effective than omeprazole initially.

Conclusions:

• BY841, a novel APA, provides effective and sustained gastric acid suppression.
• BY841 demonstrates superior initial efficacy and comparable long-term potency to omeprazole.
• BY841 represents a promising therapeutic option for managing acid-related gastrointestinal disorders.